AFQ056 treatment of levodopa-induced dyskinesias: Results of 2 randomized controlled trials

Current approaches to the treatment of Parkinson’s disease

(2011) Joseph Jankovic   Neuropsychiatric Disease and Treatment

Reduction of L-DOPA-Induced Dyskinesia by the Selective Metabotropic Glutamate Receptor 5 Antagonist 3-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]pyridine in the 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Lesioned Macaque Model of Parkinson's Disease

(2010) T. H. Johnston et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Effect of the metabotropic glutamate receptor type 5 antagonists MPEP and MTEP in parkinsonian monkeys

(2010) Nicolas Morin et al.   NEUROPHARMACOLOGY

Review: Deep brain stimulation in Parkinson’s disease

(2009) S.J. Groiss et al.   Therapeutic Advances in Neurological Disorders

mGluR5 metabotropic glutamate receptors and dyskinesias in MPTP monkeys

(2007) Pershia Samadi et al.   NEUROBIOLOGY OF AGING

Systemic administration of an mGluR5 antagonist, but not unilateral subthalamic lesion, counteracts l-DOPA-induced dyskinesias in a rodent model of Parkinson's disease

(2007) Giovanna Levandis et al.   NEUROBIOLOGY OF DISEASE